Introduction

JMML is a rare leukemia characterized by aberrant myeloid proliferation and hypersensitivity to GM-CSF. Mutually exclusive mutations in PTPN11, N/K-RAS, CBL, or NF1 are found in ~90% of patients. These mutations cause the disease at least in part by activating STAT5 through phosphorylation and promoting cell growth. MicroRNAs (miRs) are small (~22 nucleotides) noncoding RNAs, regulating gene expression and often deregulated in leukemia. We investigated whether miRs are deregulated in JMML and whether miRs target critical proteins involved in the disease pathogenesis.

Patients and Methods

MiRs expression profile of 40 bone marrow (BM) samples from untreated JMML patients and 8 BM samples from healthy controls was performed using the Ncounter Human v2 miRNA Expression Assay (nanostring). MiR150-5p and STAT5b mRNA expression were assessed using quantitative (q)RT-PCR. Selected miRs and target expression were measured in BM and spleen from a JMML (PTPN11) murine model (D61Y mutation). We overexpressed miR-150-5p in AML cell lines (K562, OCI-AML-3, KG1a) using a miR-150-5p precursor plasmid and STAT5b mRNA was assessed by qRT-PCR. STAT5 and phospho-STAT5 protein levels were assessed by Western Blot in miR-150-5p transfected AML cell lines, human JMML and mice BM cells. STAT5b 3'UTR sequence was cloned in a Firefly/Renilla Luc construct and co-transfected with miR-150-5p miRNA mimic into 293T cell line.

Results

We found that 25 miRs were differentially expressed in whole BM cells from JMML patients respect to healthy controls (Table 1). MiR-150-5p was the most downregulated miR in JMML. We focused on miR-150-5p, since it has been described to be downregulated in AML cases and is predicted to target STAT5b, a critical gene in JMML biology. We validated that miR-150-5p was down-regulated in JMML cases respect to controls performing qRT-PCR on 38 BM samples from JMML patients. Likewise, miR-150-5p was downregulated in BM and spleen samples from PTPN11 mutated mice respect to controls (0.35 and 0.27 Average Fold Change decrease respectively). STAT5 protein, a predicted target for miR-150-5p, was highly expressed in the JMML patients and mice BM samples respect to their controls (4.3 and 1.3 Average Fold Change increase respectively). MiR-150-5p overexpression in K562, OCI-AML-3 and KG1a cell lines led to decrease of STAT5 protein levels and phosphorilation at 48 hours. Direct interaction of STAT5b 3'UTR with miR-150-5p was demonstrated by luciferase assay (~50% Luc activity inhibition, P<0.001). Last, overexpression of miR-150-5p in primary JMML samples using a GFP tagged lentivirus significantly decreased cell growth respect to controls (empty vector) in response to GM-CSF (P<0.01).

Discussion

We showed that miR-150-5p is downregulated in JMML samples and in JMML animal models. Functionally, miR-150-5p directly inhibits the translation of STAT5b mRNA resulting also in a decrease of phosphorylation of STAT5 total protein. These findings identify an alternative mechanism that supports STAT5 deregulation in JMML and that could be therapeutically targeted.

Table 1.

Deregulated miRNAs in JMML

GeneAccession #P valueFold-Change (Log2)
miR-150-5p MIMAT0000451 0,001 -2,382 
let-7g-5p MIMAT0000414 0,002 -1,660 
miR-1260a MIMAT0005911 0,009 -1,592 
let-7a-5p MIMAT0000062 0,010 -1,574 
miR-4454 MIMAT0018976 0,021 -1,399 
miR-148a-3p MIMAT0000243 0,030 -1,211 
miR-146b-5p MIMAT0002809 0,009 -1,084 
miR-342-3p MIMAT0000753 0,010 -1,075 
let-7f-5p MIMAT0000067 0,021 -1,022 
miR-26a-5p MIMAT0000082 0,034 -1,008 
let-7d-5p MIMAT0000065 0,038 -1,005 
miR-30b-5p MIMAT0000420 0,019 -0,972 
miR-29b-3p MIMAT0000100 0,044 -0,956 
miR-29a-3p MIMAT0000086 0,024 -0,761 
miR-338-3p MIMAT0000763 0,042 0,654 
miR-23a-3p MIMAT0000078 0,040 0,689 
miR-222-3p MIMAT0000279 0,018 0,756 
miR-548ai MIMAT0018989 0,009 0,993 
miR-494 MIMAT0002816 0,023 1,021 
miR-320e MIMAT0015072 0,007 1,175 
miR-224-5p MIMAT0000281 0,024 1,227 
miR-4508 MIMAT0019045 0,016 1,369 
miR-575 MIMAT0003240 0,014 1,429 
miR-3195 MIMAT0015079 0,014 1,432 
miR-630 MIMAT0003299 0,001 2,272 
GeneAccession #P valueFold-Change (Log2)
miR-150-5p MIMAT0000451 0,001 -2,382 
let-7g-5p MIMAT0000414 0,002 -1,660 
miR-1260a MIMAT0005911 0,009 -1,592 
let-7a-5p MIMAT0000062 0,010 -1,574 
miR-4454 MIMAT0018976 0,021 -1,399 
miR-148a-3p MIMAT0000243 0,030 -1,211 
miR-146b-5p MIMAT0002809 0,009 -1,084 
miR-342-3p MIMAT0000753 0,010 -1,075 
let-7f-5p MIMAT0000067 0,021 -1,022 
miR-26a-5p MIMAT0000082 0,034 -1,008 
let-7d-5p MIMAT0000065 0,038 -1,005 
miR-30b-5p MIMAT0000420 0,019 -0,972 
miR-29b-3p MIMAT0000100 0,044 -0,956 
miR-29a-3p MIMAT0000086 0,024 -0,761 
miR-338-3p MIMAT0000763 0,042 0,654 
miR-23a-3p MIMAT0000078 0,040 0,689 
miR-222-3p MIMAT0000279 0,018 0,756 
miR-548ai MIMAT0018989 0,009 0,993 
miR-494 MIMAT0002816 0,023 1,021 
miR-320e MIMAT0015072 0,007 1,175 
miR-224-5p MIMAT0000281 0,024 1,227 
miR-4508 MIMAT0019045 0,016 1,369 
miR-575 MIMAT0003240 0,014 1,429 
miR-3195 MIMAT0015079 0,014 1,432 
miR-630 MIMAT0003299 0,001 2,272 

Figure 1.

miR-150-5p Relative Expression for each subset of JMML patients with different mutational profiles and Healthy Controls

Figure 1.

miR-150-5p Relative Expression for each subset of JMML patients with different mutational profiles and Healthy Controls

Close modal
Disclosures

No relevant conflicts of interest to declare.

Author notes

*

Asterisk with author names denotes non-ASH members.

Sign in via your Institution